<div id="readability-page-1"><div>By Colin Kellaher Bristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR T-cell therapy Breyanzi in a subtype of non-Hodgkin lymphoma. Bristol Myers late Thursday said the approval covers Breyanzi for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. The Princeton, N.J., biopharmaceutical company said the green light makes Breyanzi the only CAR T-cell therapy approved by the FDA for five cancer types and the only one approved for those with relapsed or refractory marginal zone lymphoma. CAR T-cell therapy involves genetically engineering a patient's own T cells to attack cancer cells. Breyanzi generated worldwide revenue of $966 million in the first nine months of 2025. Write to Colin Kellaher at colin.kellaher@wsj.com (END) Dow Jones Newswires12-05-25 0631ET</div></div>

百時美施貴寶

百時美施貴寶已獲得美國食品藥品監督管理局（FDA）對其 CAR T 細胞療法 Breyanzi 的擴展批准，用於治療成人複發性或難治性邊緣區淋巴瘤。這使得 Breyanzi 成為唯一獲得批准用於五種癌症類型的 CAR T 細胞療法，包括這一特定的淋巴瘤亞型。該療法涉及對患者的 T 細胞進行基因工程改造，以靶向癌細胞。Breyanzi 在 2025 年前九個月的收入達到了 9.66 億美元

百時美施貴寶獲得 FDA 對 Breyanzi 的擴大適應症批准